Abstracts tagged "drug therapy and psoriatic arthritis"

Abstract Number: 2618 • 2018 ACR/ARHP Annual Meeting
Drug Survival of Non TNF Inhibitors Bdmards in Psoriatic Arthritis (Ustekinumab/Secukinumab) : A Real-Word Multicentric Cohort of 161 Patients
Jean-Guillaume Letarouilly¹, Jeremie Sellam², Pascal Richette³, Philippe Dieude⁴, Pascal Claudepierre⁵, Tristan Pascart⁶, Eric Houvenagel⁶, Marie-Hélène Guyot⁷, Nicolas Segaud⁸, Pascal Coquerelle⁹, Frederic Maury¹⁰, Laurent Marguerie¹¹, Xavier Deprez¹², Jean-Hugues Salmon¹³, Guy Baudens¹², Elisabeth Gervais¹⁴, Maeva Kyheng¹⁵, Julien Paccou¹ and René-Marc Flipo¹, ¹Rheumatology, Lille University Hospital, Lille, France, ²AP-HP Saint-Antoine hospital, Service de Rhumatologie, Inserm UMRS_938, Paris, France, ³Rheumatology, Université Paris Diderot, Paris, France, ⁴Université Paris-Diderot, Paris, France, ⁵Hôpital Henri Mondor, Créteil, France, ⁶Rheumatology, Groupe Hospitalier de l'Institut Catholique de Lille, Lomme, France, ⁷Internal medicine, Hospital of Roubaix, Roubaix, France, ⁸Internal medicine, Hospital of Armentieres, Armentières, France, ⁹rheumatology, Hospital of Bethune, Bethune, France, ¹⁰Rheumatology, Private Practice, Beuvry, France, ¹¹Rheumatology, Institut Calot, Berck, France, ¹²Rheumatology, CHR Valenciennes, Valenciennes, France, ¹³Service de Rhumatologie, CHU Reims, Hôpital Maison Blanche, Reims, France, ¹⁴Rhumatologie, University Hospital, Poitiers, France, ¹⁵Lille University Hospital, EA 2694 - Santé publique : épidémiologie et qualité des soins, F-59000, Lille, France
Background/Purpose: Ustekinumab and secukinumab are two new Biologic Disease-modifying Antirheumatic Drugs (bDMARDs) in severe psoriatic arthritis (PsA), targeting respectively IL12-23 and IL 17. Data in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].